{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-011120","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.701657+00:00","generated_at":"2026-06-26T03:19:42.371053+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Esperion appoints Stephen Rocamboli to board; Dr. Mark McGovern resigns","bullets":["Mark McGovern resigned from board effective April 28, 2022; no disagreement cited.","Stephen Rocamboli elected to fill vacancy; will serve on Audit Committee.","Rocamboli is CEO of Perla Therapeutics, with prior life science board and executive roles.","Esperion expects topline readout of CLEAR Outcomes trial in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-011120","json":"https://secwatch.observer/filing/0001628280-22-011120.json","markdown":"https://secwatch.observer/filing/0001628280-22-011120.md","text":"https://secwatch.observer/filing/0001628280-22-011120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/espr-20220428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:19:42.371053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d1969061e","claim":"Mark E. McGovern resigned as Director at Esperion Therapeutics, Inc..","evidence_excerpt":"On April 28, 2022, Mark E. McGovern, M.D. notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) of his decision to resign from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"49781c0be7","claim":"Stephen Rocamboli was elected as Director at Esperion Therapeutics, Inc..","evidence_excerpt":"On April 28, 2022, the Board elected Stephen Rocamboli to fill the newly created vacancy on the Board resulting from Dr. McGovern’s resignation from the Board, effective April 28, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}